6. パーキンソン病 Parkinson disease Clinical trials / Disease details

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

6 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04643327 (ClinicalTrials.gov)	February 9, 2021	18/11/2020	Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease	Double-blind Randomised-controlled Within-subject Crossover Trial to Determine Levetiracetam Efficacy for Memory Impairment in Parkinson's Disease: A Proof-of-concept Study	Parkinson Disease;Mild Cognitive Impairment;Memory Impairment	Drug: Levetiracetam;Drug: Placebo	The University of Queensland	Johns Hopkins University;Cleveland Clinic Lou Ruvo Center for Brain Health;Royal Brisbane and Women's Hospital;Queensland University of Technology	Recruiting	N/A	N/A	All	28	Phase 2	Australia
2	NCT00584025 (ClinicalTrials.gov)	December 2007	21/12/2007	Keppra IV for the Treatment of Motor Fluctuations in Parkinson's Disease		Parkinson's Disease	Drug: levetiracetam;Drug: Placebo	University of South Florida	NULL	Withdrawn	30 Years	80 Years	All	0	Phase 4	United States
3	NCT00291733 (ClinicalTrials.gov)	May 2006	14/2/2006	Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease	Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease: A Double-Blind,Placebo-Controlled, Crossover Trial	Levodopa Induced Dyskinesia	Drug: Levetiracetam;Drug: Placebo	1st Hospital of Social Security Services	UCB Pharma	Active, not recruiting	30 Years	80 Years	Both	50	Phase 2	Greece
4	NCT00307450 (ClinicalTrials.gov)	March 2006	27/3/2006	Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease	Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease (LeLeDys Study) - A Multicenter, Randomized, Stratified, Double-blinded, Placebo-controlled Phase IV Study	Parkinson's Disease	Drug: Levetiracetam	Technische Universität Dresden	UCB GmbH, Huettenstrasse 205, 50170 Kerpen, Germany	Completed	30 Years	80 Years	Both	34	Phase 4	Germany
5	NCT00076674 (ClinicalTrials.gov)	January 2004	28/1/2004	Levetiracetam Treatment of L-dopa Induced Dyskinesias	Levetiracetam Treatment of L-dopa Induced Dyskinesias	Dyskinesias;Parkinson Disease	Drug: Intravenous Levodopa	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	N/A	N/A	Both	40	Phase 2	United States
6	NCT00160576 (ClinicalTrials.gov)	July 2003	8/9/2005	Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias	A Therapeutic Exploratory, Single Arm, Multicenter Trial to Evaluate the Efficacy and Safety of Levetiracetam up to 4000 mg/Day (500mg Oral Tablets) on Levodopa Induced Dyskinesias in Adults With Idiopathic Parkinson's Disease	Idiopathic Parkinson Disease	Drug: Levetiracetam	UCB Pharma	NULL	Completed	30 Years	N/A	Both	30	Phase 2	NULL

先頭へ